Macartney K, et al. - Researchers contemplated the upshot of measles-mumps-rubella-varicella (MMRV) vaccine as the second dose of measles-containing vaccine (MCV) on the safety and coverage of earlier (age 18 months) scheduling of this vaccine, in Australia. No connection was revealed between the use of MMRV vaccine as the second dose of MCV in toddlers and an increased risk of febrile seizures. Improvements were gained in the vaccine coverage through the incorporation of MMRV vaccine. This would potentially improve the disease control.